Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium [Gastrointestinal Cancer]
Conclusion
mDCF is less toxic than parent DCF, even when supported with growth factors, and is associated with improved efficacy. mDCF should be considered a standard first-line option for patients with metastatic gastric or GEJ adenocarcinoma.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Shah, Janjigian, Stoller, Shibata, Kemeny, Krishnamurthi, Su, Ocean, Capanu, Mehrotra, Ritch, Henderson, Kelsen Tags: Chemotherapy Gastrointestinal Cancer Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Gastric (Stomach) Cancer | Gastroenterology | Study | Taxotere | Toxicology